Last reviewed · How we verify
lopinavir/ritonavir (LPV/r)
lopinavir/ritonavir (LPV/r) is a Protease inhibitor Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV. Also known as: ABT-378, lopinavir/ritonavir, LPV/r, Kaletra.
Lopinavir/ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus.
Lopinavir/ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | lopinavir/ritonavir (LPV/r) |
|---|---|
| Also known as | ABT-378, lopinavir/ritonavir, LPV/r, Kaletra, Aluvia |
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | Protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Lopinavir/ritonavir works by inhibiting the protease enzyme, which is essential for the maturation of viral particles. This prevents the virus from replicating and reduces the viral load in the body. Ritonavir is a booster that increases the levels of lopinavir in the body, allowing for a lower dose and reducing side effects.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Bone and Body Comp: A Sub Study of the SECOND-LINE Study (PHASE4)
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r (PHASE4)
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lopinavir/ritonavir (LPV/r) CI brief — competitive landscape report
- lopinavir/ritonavir (LPV/r) updates RSS · CI watch RSS
- French National Agency for Research on AIDS and Viral Hepatitis portfolio CI
Frequently asked questions about lopinavir/ritonavir (LPV/r)
What is lopinavir/ritonavir (LPV/r)?
How does lopinavir/ritonavir (LPV/r) work?
What is lopinavir/ritonavir (LPV/r) used for?
Who makes lopinavir/ritonavir (LPV/r)?
Is lopinavir/ritonavir (LPV/r) also known as anything else?
What drug class is lopinavir/ritonavir (LPV/r) in?
What development phase is lopinavir/ritonavir (LPV/r) in?
What are the side effects of lopinavir/ritonavir (LPV/r)?
What does lopinavir/ritonavir (LPV/r) target?
Related
- Drug class: All Protease inhibitor drugs
- Target: All drugs targeting HIV-1 protease
- Manufacturer: French National Agency for Research on AIDS and Viral Hepatitis — full pipeline
- Therapeutic area: All drugs in Infectious disease
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Indication: Drugs for Prevention of mother-to-child transmission of HIV
- Also known as: ABT-378, lopinavir/ritonavir, LPV/r, Kaletra, Aluvia
- Compare: lopinavir/ritonavir (LPV/r) vs similar drugs
- Pricing: lopinavir/ritonavir (LPV/r) cost, discount & access